Earnings call transcript: Abeona Therapeutics Q2 2025 reports unexpected profit

Abeona Therapeutics (ABEO) surprised investors with its Q2 2025 earnings, reporting an unexpected profit. The company achieved an earnings per share (EPS) of $1.71, significantly exceeding the forecasted EPS of -$0.38, marking a 550% surprise. Revenue reached $400,000, against no revenue forecast. Following the earnings announcement, Abeona’s stock rose by 10.21% in pre-market trading, closing at $7.23, just 1% below its 52-week high of $7.32. According to InvestingPro data, the stock has delivered impressive returns of 15.5% in the past week and 29.8% year-to-date.

Key Takeaways

• Abeona Therapeutics reported an EPS of $1.71, significantly above expectations.
• Revenue for Q2 2025 was $400,000, with no prior forecast.
• Stock surged by 10.21% in pre-market trading, reflecting investor optimism.
• FDA approval of ZevaSkin in April 2025 boosted market confidence.
• The company anticipates profitability by early 2026.

Company Performance

Abeona Therapeutics demonstrated strong performance in Q2 2025, reporting a net income of $108.8 million, translating to $2.07 per basic share. This marks a significant improvement from previous quarters and reflects the company’s successful strategic initiatives. The FDA approval of ZevaSkin, the first autologous cell-based gene therapy for Receptive Dystrophic Epidomyolysis Bullosa (RDEB), has positioned Abeona as a leader in the gene therapy market.

Financial Highlights

• Revenue: $400,000 (no prior forecast)
• Earnings per share: $1.71 (forecast was -$0.38)
• Cash and cash equivalents: $225.9 million as of June 30, 2025
• R&D expenses: $5.9 million in Q2 2025 (down from $9.2 million in Q2 2024)
• SG&A expenses: $17.1 million in Q2 2025 (up from $8.6 million in Q2 2024)

Earnings vs. Forecast

Abeona Therapeutics reported an EPS of $1.71, significantly outperforming the forecasted loss of $0.38 per share. The 550% surprise highlights the company’s robust financial health and strategic execution. This unexpected profit contrasts with previous quarters, where the company faced challenges in meeting earnings expectations.

Market Reaction

Following the earnings announcement, Abeona’s stock price surged by 10.21% in pre-market trading, closing at $7.23. This positive market reaction reflects investor confidence in the company’s strategic direction and financial performance. The stock is nearing its 52-week high of $7.32, indicating strong market momentum. InvestingPro analysis suggests the stock is currently overvalued, with analyst price targets ranging from $11 to $27.50. The RSI indicates overbought conditions, warranting careful consideration for potential investors.

Outlook & Guidance

Looking ahead, Abeona Therapeutics anticipates achieving company-wide profitability by early 2026. The company plans to expand its manufacturing capacity to accommodate 10 patients per month by mid-2026. Abeona is also exploring international market opportunities in the EU and Japan, with an eye on expanding its Qualified Treatment Centers (QTCs).

Executive Commentary

CEO Vish Seshadri stated, "ZivaSkin is the first and only autologous cell-based gene therapy for the treatment of adult and pediatric patients with Receptive Dystrophic Epidomyolysis Bullosa." This milestone underscores Abeona’s leadership in the gene therapy sector. Chief Commercial Officer Madhav Vasanthada added, "We remain optimistic about our ability to treat 10 to 14 patients this year," highlighting the company’s commitment to patient care and market expansion.

Risks and Challenges

• Regulatory hurdles in international markets could delay expansion plans.
• Competition from emerging gene therapies may impact market share.
• Economic uncertainties could affect healthcare spending and reimbursement rates.
• Manufacturing capacity expansion may face logistical challenges.
• Dependence on a limited number of QTCs could constrain patient access.

Q&A

During the earnings call, analysts inquired about the patient identification process, focusing on severe RDEB patients. Executives emphasized the positive impact of patient testimonials in driving community interest. Analysts also expressed interest in the company’s plans for international expansion and manufacturing capacity growth, to which Abeona’s leadership provided reassurances about their strategic roadmap.

Full transcript - Abeona Therapeutics Inc (ABEO) Q2 2025:

Conference Operator: Good day, everyone, and welcome to the Abeona Therapeutics Second Quarter twenty twenty five Conference Call. Listen It is now my pleasure to turn the floor over to your host, Greg Jin, VP of Investor Relations and Corporate Communications. Sir, the floor is yours.

Greg Jin, VP of Investor Relations and Corporate Communications, Abeona Therapeutics: Thank you, Matt. Good morning, and thank you for joining us on our second quarter twenty twenty five results conference call. During this call, we will refer to the press release this morning announcing the financial results, which is available on our corporate website at www.abionatherapeutics.com. We anticipate making projections and forward looking statements during today’s call, which are made pursuant to the Safe Harbor provisions of the federal securities laws. These forward looking statements are based on current expectations and are subject to change.

Actual results may differ materially from those expressed or implied in the forward looking statements due to various factors, including, but not limited to, those outlined in our Form 10 ks and periodic reports filed with the SEC. These documents are available on our website at www.aviotherapeutics.com. Joining me on today’s call with prepared remarks are Doctor. Vish Sehajadri, Chief Executive Officer Doctor. Amada Visankivada, Chief Commercial Officer and Joe Visano, Chief Financial Officer.

Also, Doctor. Brian Keveney, Chief Executive Officer, will join us for the Q and A session. And with that, I will now turn the call over to Vish Seshadri to lead us off. Vish?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Thank you, Greg, and good morning, everyone. The 2025 marked the biggest milestone achievements in Avionna’s history so far with the FDA approval of ZevaSkin in April. ZevaSkin is the first and only autologous cell based gene therapy for the treatment of adult and pediatric patients with Receptive Dystrophic Epidomyolysis Bullosa or RDEB. There is a persistent unmet need to meaningfully heal RDEB wounds. Since ZivaSkin’s approval, the enthusiasm and positive feedback from the RDEB community has further increased our confidence that ZivaSkin will become an important treatment option for people with RDEB.

We’re already seeing positive momentum in the early stage of our launch. We’re now accepting patients and referrals from healthcare providers to initiate ZevaSkin treatment at both our activated qualified treatment centers or QTCs, which are Lurie Children’s Hospital of Chicago and Lucille Packard Children’s Hospital of Stanford. We are on track for the first zero skin patient treatment and thus anticipate first commercial revenues in the 2025. With the commercial launch tracking to plan and with encouraging feedback from QTC’s physicians and the patient community, we’re very excited about ZevaSkin’s potential to improve the lives of people with RDEB. To dive deeper into our launch progress and the momentum in greater detail, I’ll now hand the call to our Chief Commercial Officer, Doctor.

Madhav Vasanthada. Madhav? Thanks, Vish, and good morning, everyone. We are actively executing on our launch strategy, and I will provide specific updates on our initial progress, the near term demand trends, the process for scheduling patients onto treatment and our momentum with payers. In the first three months since ZivaSkin’s approval, we have seen strong interest from the EB community.

The two qualified treatment centers that have been onboarded have already identified more than a dozen patients as candidates for ZivaSkin, and the process is underway to initiate their treatment. Moreover, we understand that referring physicians from other centers that are not QTCs have identified nearly three dozen additional immediate candidates. We expect patient referrals to further build as our promotional activities generate more ZevaSkin awareness in the marketplace. With a total of approximately 50 identified patients and that number growing, we are actively working with Lurie and Stanford Children’s to initiate treatment of those patients in the coming quarters, and we remain optimistic about our ability to treat 10 to 14 patients in 2025, as previously mentioned. In parallel, we are on track to increase our manufacturing capacity to treat 10 patients per month in mid-twenty twenty six.

While the volume of identified patients at our two existing QTC is encouraging from a demand perspective, we will continue to activate additional QTCs to ease the travel burden on patients by expanding ZevaSkin’s geographic footprint, which we expect to further grow patient demand. We will announce new centers when they are ready to treat patients. Before I discuss the process for scheduling patients onto treatment, let me preface that the administrative process associated with Ziva Skin during this early launch phase requires a long lead time and involves significant logistical steps. Currently, we project that the journey from patient identification to ZivaScan treatment will take approximately three to four months, and we anticipate this time frame will shorten and scheduling will become more predictable as our launch progresses, as we activate additional QDCs, and as established QDCs gain experience. Let me provide an overview of the administrative steps involved in Ziva Skin treatment.

The patient journey begins with an initial consultation with the physician at the QTC, which is then followed by payer medical authorization that can take a week or more. The next step of securing the next step of securing payer financial agreement for that patient can take approximately four to six weeks. Once these steps are complete, the patient’s biopsy is scheduled based on availability of both the patient and the care team. Our twenty five day manufacturing process begins immediately after biopsy is received at our manufacturing facility and culminates in the patient’s return to the QTC for treatment, which is when we recognize revenue. Throughout this journey, our Adrenoyasys patient navigators are ready and committed to supporting patients and the centers dealing with the logistics of biopsy and return to the QTC for treatment.

Now despite all these logistical steps, we are happy to report the successful completion of our first commercial patient biopsy at Lurie Children’s Hospital. Manufacturing is underway and we expect this patient to receive treatment soon. Now turning to payers. We have made significant progress in securing widespread insurance coverage for ZeevaSkin. It’s important to remember that sixty percent of RDEB lives are covered by commercial plans, thirty percent by Medicaid, and the rest by Medicare.

To date, we have achieved positive coverage with multiple national and regional payers. Importantly, even in the absence of formal coverage policies, Ziva Skin is being accessed through medical exception process. The prior authorization process has been highly successful with 100% of requests approved to date, including for Medicaid patients with some approvals received as soon as within forty eight hours. Now this demonstrates strong clinical acceptance of ZivaSkin among payers. The most notable milestone with regards to commercial payers is the recent decision by UnitedHealthcare, the largest commercial payer in The U.

S, to cover ZivaSkin in line with its FDA approved label and with no additional restrictions. We hope that this sets a critical precedent for other payers and that it will be a major step towards ensuring broad access and we are optimistic that this positive momentum with payers will continue. On the Medicaid front, we reached a key milestone by entering into a National Drug Rebate Agreement, NDRA, with CMS and taking the steps necessary to ensure coverage across all 51 state Medicaid programs and Puerto Rico. In parallel, we are driving productive discussions to expedite coverage and reimbursement with the majority of state Medicaid programs and this is already yielding results as states implement favorable Medicaid coverage criteria for ZivaSkin. Overall, we are encouraged by these early market access trends.

Finally, turning to our engagement with the RDEB community, the patient and community response continues to be exceptionally positive. We recently partnered with Deborah of America for a nationally broadcast webinar where a clinical trial patient shared her individual experience of durable wound healing following a single application. This patient received VeevaSkin twice during our clinical trials to cover different wound areas. We are encouraged that so far she has been experiencing durable healing even three and a half years after treatment. We also engaged directly with RDEB families at three regional meetups at Columbia Presbyterian in New York City, Cincinnati Children’s, and the University of South Carolina in Los Angeles, where three unique patients from our Strong Together network shared their XevaSkin stories and showed their present day images of their still intact treated wounds.

All three have so far experienced durable wound healing from their single treatment in clinical trials. Two received treatment nearly four years ago and one patient who received treatment seven years ago. In summary, we are encouraged by our initial launch progress with nearly 50 ZEVASKIN patients having been identified between our two activated QTCs and a growing number of referrals. We remain optimistic about our ability to treat 10 to 14 patients this year. We are also actively on boarding new QTCs this year to further expand patient access.

Reimbursement trends are strong and the clinical interest from patients and physicians highlight ZivaSkin’s value proposition of providing significant wound healing from a single surgical application. As Q2Cs gain experience, we expect the centers to identify and treat more patients. With that, I will now pass the call over to our Chief Financial Officer, Joe Vazano, to discuss our financial results. Joe?

Joe Vazano, Chief Financial Officer, Abeona Therapeutics: Thanks, Madhav. I would like to remind everyone that you can find additional details on our financial results for the three six months ended 06/30/2025, in our most recent Form 10 Q, which is available on our website. Starting with the financial resources on our balance sheet. We had unaudited cash, cash equivalents, short term investments and restricted cash of $225,900,000 as of 06/30/2025, which includes the net proceeds of the sale of the Priority Review Voucher that we received with ZivaSkin approval. This compares to $98,100,000 as of 12/31/2024.

Our existing cash resources provide Abeona with robust financial flexibility, providing over two years of operating capital, put out on our forecast without the need for further capital infusion and prior to accounting for ZivaSkin sales. We anticipate that the first ZivaSkin patient treatment will occur in the 2025, which will initiate revenue generation, leading to our projected company wide profitability in early twenty twenty six. As a reminder, revenue recognition occurs when the patient receives ZivaSkin, that is upon surgical application. At this early stage in our launch, it is premature to provide revenue guidance. A quick note on our financial reporting going forward.

As we transition into a revenue generating commercial company, we will move away from providing cash runway guidance given the complexities of estimating future revenues in the early launch phase. In lieu of runway guidance, we plan to provide high level forward cost guidance alongside regular updates on the commercialization and progress. Now turning to the statements of operations. Research and development expenses were $5,900,000 for the quarter ended 06/30/2025, compared to $9,200,000 for the quarter ended 06/30/2024. The reduction in R and D expense was primarily due to costs capitalized into inventory and select costs such as engineering runs and other production costs reclassified as selling, general and administrative, or SG and A, expense following the approval of Zevsky.

Our spend on SG and A activities was $17,100,000 for the quarter ended 06/30/2025, compared to $8,600,000 for the quarter ended 06/30/2024. In addition to the reclassification of select R and D expense to SG and A, the increase in SG and A reflects increased headcount and professional costs associated with the commercial launch of ZYDOSIT. Net income was $108,800,000 for the 2025 or $2.07 per basic and $1.71 per diluted common share, including the gain from the sale of the PRB. Net income in the 2024 was $7,400,000 or $0.19 per basic and a net loss of $0.26 per diluted common share. In terms of upcoming Investor Relations activity, we plan to participate in two investor conferences in September, the Cantor Global Healthcare Conference and H.

C. Wainwright Annual Global Investment Conference. And with that, I’ll pass the call back to Vish for additional remarks before opening the call for Q and A.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Thank you, Joe. Turning to our pipeline. Beacon Therapeutics has exercised its option for non exclusive license to the patented AAV204 capsid for use in retinal diseases and genetic targets that are non redundant with our AAV ophthalmology pipeline. As a reminder, AAV204 has been shown to achieve high macular and optic nerve transduction levels after pararetinal administration and has also been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and nonhuman primates. Now, I want to turn to another partner pipeline program, AAV gene therapy UX111, which is being developed by Ultragenyx for Sanfilippo syndrome type A or MPS IIIA.

In July, Ultragenyx reported that the FDA issued a CRL in its review of the UX111 BLA requesting additional information and improvements on CMC procedures and validation. The FDA also provided observations from the manufacturing facility inspections. Ultragenyx believes the observations are readily addressable and many have already been addressed. On its 2Q twenty five call last week, Alvogenix noted that it aims to reach agreement on its plan to resolve the CRL observations through a Type A meeting with the FDA and upon BLA resubmission expects a priority review of up to six months. Next, I turn to another partnered pipeline program, AAV gene therapy TSHA-one hundred and two, which is being developed by Tisha Gene Therapies for the treatment of Rett syndrome.

In May, Tisha reported that it secured FDA alignment on both key elements of its pivotal trial design for TSHA-one 102 and the next steps to enable the initiation of the pivotal trials that could support a potential BLA submission. Teisha has subsequently commenced pivotal trial site activation and expect to begin patient enrollment in the 2025. In June, clinical data highlighting the therapeutic potential of ESHA-one hundred two were presented at the twenty twenty five International Rett Syndrome Foundation Rett Syndrome Scientific Meeting. With that, I will open the call for Q and A. Operator, please open the Q and A session.

Conference Operator: Certainly. Everyone at this time will be conducting a question and answer session. If you have any questions or comments, please press star one on your phone at this time. We do ask that while posing your question, please pick up your handset if you’re listening on speakerphone to provide optimum sound quality. Your first question is coming from Kristen Kluski from Cantor.

Your line is live.

Kristen Kluski, Analyst, Cantor: Nice to see there’s so much momentum out of the gate. First, I wanted to just ask about how you’re specifically defining identified patients. Are these patients that have wound profiles that might make them good candidates for ZivaSkin? Or are these patients that have indicated that they’re potentially interested in receiving the treatment?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Sure. Good morning, Kristen. Madhav, can you please take that one? Yes, absolutely. Thanks, Kristen, for that question.

So these patients that have been identified are really coming from the physicians, and physicians’ criteria at this moment are for severe or deaf patients. And severe defined as patients with large wounds that have never healed in their lifetime so far. So we are really talking about really the most clinically burdened patients and physicians are very confident that these patients will get, you know, will want to get ZivaSkin treatment. So that’s really how they are looking at it. And again, this is really a tip of the pool of patients that they have, and that’s really the type of patients they want to prioritize first.

Kristen Kluski, Analyst, Cantor: Thank you for that. And then given that there’s about 36 plus of these that are not specifically within the two QTCs, how should we be thinking about when they’ll get treated? Is it that it’s I know you still have a few more that you’re planning to open. So is it possible that they might wait for one of those? Or is there just going to be more travel involved for these patients?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes. So, these patients have already started the process of referrals of those 3,036 some patients that we’ve discussed. And those patients are coming to QTCs going through the initial consult already. And for us, the way we are looking at it is with nearly 50 patients identified, pretty much the initial demand, the work is cut out in that regard to get these patients onto treatment as soon as possible while in the process of activating additional treatment centers. And as I mentioned, those additional treatment centers will certainly make it easier in terms of travel for these patients, but also there are more patients in these QTCs that will could be identified.

Kristen Kluski, Analyst, Cantor: Okay. And then last question from me. We had heard from the advocacy group that essentially all of the patients that participated in the trial said that if they had the option, they would do it again because of the benefits. So I know you have this Aviona Assist program that’s been instrumental to help the whole patient journey, but how critical has been the FaceTime or the conversations between patients that have already had ZivaSkin through the trial that are now talking to potential patients that may want it in the commercial setting? Thank you again.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: It’s been really helpful for the patients from our Strong Together network, who, again, as a reminder, are clinical trial patients who have seen, the type of benefits, durable, long lasting wound healing, for them to talk directly with RDEB families, especially in these regional meetups that I mentioned. We’ve had these patients talking one on one and answering and addressing any questions. And when the rest of the community are seeing the type of healing that their patients experience, it’s definitely motivating for the other patients. Yeah, and also, Kristen, to your question, yes, we believe this disease trial patients were pretty much treated in Stanford. Some of them have expressed interest in getting other areas treated as well.

So they will be in that pool, not necessarily the Avionna Assist because these are already patients that have the relationship with the QTC. So they are directly in touch with Stanford. Hope that addresses the question.

Tully, Analyst, Stifel: Yes, thank you.

Conference Operator: Thank you. Your next question is coming from Raycroft from Jefferies. Your line is live.

Amin, Analyst, Jefferies: Hi, this is Amin on for Maury. Thank you for taking our questions and congrats on the progress. Two from us. First, basically in your view, how many cases does a center of excellence typically need to treat before adopting PD cell as a like a routine therapy? And is there max capacity for number of surgeries per month that these centers can handle?

And I have a follow-up.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes, good morning. So it sounds like your question is more about the site’s own capacity and whether we have criteria for site selection based on what volume of patients makes it a QTC qualifiable site. Is that correct?

Amin, Analyst, Jefferies: Yes. Partly that and partly I wanted to know if there is a number that you think each of these centers need to do the surgery to become comfortable with the entire process and to start to adopt this sort of treatment routinely?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Sure, sure. I can take I can give you a short answer, and Martha will elaborate if needed. In terms of the number of pretreatments, right, I mean, there are sites that will have their very first ZivaSkin treatment at their commercial treatment experience. There is no practice treatment per se unless they’ve been part of the clinical trial site. So the only two sites that may have a repeat patient coming is, you know, or prior experience actually surgically applying is going to be Stanford or UMass.

But that being said, the other sites, for example, you can even take Chicago, LURIs, and whatnot clinical trial sites. The very first patient that they will be treating is a commercial patient. So there is no dry run for patient treatment that way. But they have experience treating a large number of RDEB patients because we’ve chosen our site. If you really look at it, the treatment experience for patients has to do with how many specialties have seen such patients, right?

The anesthesiologist, surgeons being comfortable, and the EB champion physician who’s the pediatric dermatologist in this case. So that infrastructure is the most important thing, and they do have that. Madhav, we can add with numbers or prior experience treating RDEB patients generally at the centers that are QTCs. Yeah, I’ll just say that early on, physicians at the QTC, so at Chicago, for example, wanted to first treat one or two patients before even identifying additional patients. But now we are seeing that even though our first patient has not been treated yet, the as they are talking to more patients and the conviction, they’ve already started identifying more patients even without treating the very first patient.

And these additional patients are currently going through the payer approval process. So that just speaks to the volume of conviction that these centers have just given ZivaSkin’s profile and all the clinical data generated, and that is very encouraging. But with regards to the efficiencies of the process flow, etcetera, I think once one or two patients are treated at the at, let’s say, at Lurie Children’s, that’s enough for them to scale this to go to the additional patients that they have, in their routine care and offer ZivaSkin to more patients. That’s what we are hearing from the centers. Does that Yes,

Amin, Analyst, Jefferies: yes, absolutely. Thanks. And for the other three centers you are planning to open, do you have a sense of what the RWA patient numbers might look like there? Would those be similar to what we are seeing from the first two?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: It’s about a couple of dozen patients based on our initial discussions we had with these centers, bottom up. We also were able to triangulate that with a claims analysis. So these patients are disproportionately located in these centers. And so even the dozen patients that we have said so far, that had these two So this is just a snapshot in time. And with the new QTCs that we identified, certainly there are more patients and these centers, they have EB clinics that typically tend to meet on like on a monthly basis.

Patients come in for their consult day. So as these EB clinic meetings and monthly consults happen, that gives an opportunity for these physicians to actually talk to their patients that are coming in and offering ZivaSkin to more patients. So we see this is all going to be a compounding effect of patients being identified and, you know, in the funnel.

Amin, Analyst, Jefferies: Okay. Thank you very much.

Conference Operator: Thank you. Your next question is coming from Steven Wiley from Stifel. Your line is live.

Tully, Analyst, Stifel: Hey, good morning guys. Congrats on the progress and this is Tully on for Steve. So I just have two questions, and I have a follow-up for Joe. My first question is related to activation of other QTCs. So when it comes to activating other QTCs in the future, how do think about it?

Should we think that there is Children’s Hospital as a reliable proxy for these upcoming QTCs? And also another one related to more future commercial guidance. So with these two activated, already activated Q2Cs, do you think you will be able to achieve the lower end of your patient guidance range? And then I’ll have a follow-up for Joe. Thanks.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes. I’ll let Madhav answer that question. But I just wanted to have a clarifying question back, which is, when you say ZULI is a proxy, do you mean in terms of patient numbers or experience? Can you just clarify that point?

Tully, Analyst, Stifel: Yeah. More like a patient number. Yeah.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Got it. Got it. The short answer is that with just the two QTCs, we have as Madhav gave numbers, we have enough patients to, you know, treat in the near term, which is 2025 treatments that we’ve communicated. We’re really when we’re talking about the funnel and the 50 patients that are being identified, it’s really building momentum for 2026, right, because of our manufacturing capacity is also ramping up as we speak. But go ahead, Madhav.

You have more granular everyday look into this. No, nothing more to add, Debish. You captured it well. We have, you know, we have the demand. It’s really a matter of how quickly we can put these patients on treatment, you know, in this particular year.

But as Vish reiterated, again, we have, you know, in terms of patient volume, sufficient work cut out for us, and that’s really going to be in the coming quarters. That’s going to be our focus, while at the same time, of course, trying to ramp additional sites as well.

Tully, Analyst, Stifel: Thank you.

Conference Operator: Thank you. Your next question is coming from Ram Selvaraju from H. C. Wainwright. Your line is live.

Ram Selvaraju, Analyst, H.C. Wainwright: Thanks very much for taking my questions. I was wondering if you could just comment on two aspects regarding the mechanics of payment and reimbursement for ZivaSkin. Firstly, are there differences in the ways in which you receive payment for ZivaSkin or that you are in the ways you are you are envisaging receiving payment for ZivaSkin related to the process of administration? Like, for example, in every case, is the payment for the product all received and booked upfront? Or is part of it staged as patients move through the treatment process?

And secondly, I was wondering if you could comment on the prior authorization situation, if you’re seeing any emergent trends indicating, intent by any reimbursement agency to ask for, patient status with respect to other RDEB treatments, the extent to which other RDEB treatments had already been tried before approving Ziva Skin, or if you don’t expect that to ever be something that emerges in the future? Thank you.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Great questions, Ram. I thought you’re the right person for both. If I just have to recap, just to be clear, the first one was more about the reimbursement mechanics of what triggers payment and if there’s different ways in which dollars are paid. And the second one is more about the prior authorization process, looking at what other treatments these are the patients and using that as a gating factor for Edmoder. Right.

Thanks, Tom, for those questions, Anvish. So the payment is not gated through the process. The payment is or the revenue is recognized after a patient has been treated with Zika Skin. So that’s in terms of Abeona booking the revenue for that patient. And I will just add on that in terms of the procurement process, there are two pathways by which a hospital can procure the product, either directly from Adiona, or the other channel is through a specialty pharmacy.

And in both cases, revenue is recognized after the product is treated. In terms of the in terms of the prior auth process and the financial agreement, the good part here is that the hospital is able to come to an agreement with payer even before placing, an order for the product with Abeona. So that just minimizes any kind of risk that the hospital also has got, you know, in this. So so that is a that’s just how the mechanics of working with regards to the the payment. Does that let me pause there, and, Ram, does that answer your question before I talk about the therapies?

Ram Selvaraju, Analyst, H.C. Wainwright: Yes. No. That’s very clear. Thank you.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Okay. Great. And then with regards to your second question, so far we have not received any pushback from payers or any kind of resistance about that the patient should not have or should have received other approved treatments before getting ZivaSkin. And all of our conversations we’ve been having, and this is really a kudos to the payers for realizing the value and the value proposition of ZivaSkin because you’ve got a therapy here that has the ability to treat vast areas of the body and be recognized the high clinical burden on these patients with durable wound healing. And that is resonating well.

So we hope that that trend will continue as payers also institute policies.

Joe Vazano, Chief Financial Officer, Abeona Therapeutics: Thank you very much.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Thank you.

Conference Operator: Your next question is coming from Jeff Jones from Oppenheimer. Your line is live.

Ram Selvaraju, Analyst, H.C. Wainwright: Good morning, folks, and thanks for taking the question. Really appreciate the degree of granularity you’re providing here. You mentioned 100% success rate on submitted prior authorizations. As we think about the time line leading into then biopsies and eventual treatment, can you comment on how many prior authorizations have been submitted at this point? And as we think about timelines for the one biopsy done so far, if you’re anticipating additional biopsies this quarter that would lead to treatments this quarter.

And then I have a follow-up.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes. Thank you, Jeff, for that question. We can definitely share the numbers. But the thing is the prior ops that are in process are more than the ones that are approved, right? So the first four or five or something like that, have seen that we’ve been able to get to the prior auth approvals, but it’s a dynamic number.

As we speak, these numbers keep changing. So I don’t want to throw out any numbers prematurely. But in regards to the time aspect that you asked, right, I mean, long would it take for these prior auths? I think that process is getting shorter and shorter. We are right now at a phase where not all calls have been put in place, and prior auths are happening as, you know, medical exceptions.

So even with that scenario, to see the patients going through the prior auth process coming out the other end eventually with an approval is very encouraging. It’s more qualitatively the nature of no blockage per se is what we want to communicate at this point in time. It’s premature to give reimbursement success metrics otherwise because, you know, we have to look at trends over one or two quarters. But what we do have confidence is that the number of patients that are going through the funnel, I don’t want to give specific biopsy numbers for Q3 versus Q4 and things like that. But just from the number of patients and the demand and have been in the funnel so far, we feel optimistic that the 10 to 14 estimate that we’ve provided still remains very achievable, and we’re looking forward to attending that goal.

Ram Selvaraju, Analyst, H.C. Wainwright: Great. Really appreciate it. And one follow-up question. As we talk about that ramp for patient dosing and the issue of production capacity, and I know you’re looking at production capacity of 10 per month by mid-twenty six. Can you speak to any hurdles or risks there to that capacity coming online?

Any concerns regarding FDA inspections, for example, given all of the events we’ve seen at the agency of late?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes. I think our the current CGMP facility that we already have has the space capacity to get up to 10. And as previously communicated, we it goes in steps of building two patients every And we have done all the hiring and space adjustments that we needed to do in order to have that 10 by mid next year. For more details around what are the processes, I wouldn’t say risks in terms of catastrophic risks, but is there an FDA action involved? Yes.

To go beyond six to 10, we do need to have some approved by the FDA. But I’ll have our Chief Clinical Officer, Doctor. Brian Keveney, on our plans so far and why we feel good about this is on track. Brian, can you add some color?

Greg Jin, VP of Investor Relations and Corporate Communications, Abeona Therapeutics: Yes.

Brian Keveney, Chief Clinical Officer, Abeona Therapeutics: Thanks, Vish. Yes. So I would say our previous communications around this topic, are exactly in line with where we anticipated being at this point. The ramp to from clinical to commercial manufacturing has gone extremely well. Hiring, training, having the facility ready for that production has gone just how we hoped it would go.

And we are still on track to meet that goal at

Joe Vazano, Chief Financial Officer, Abeona Therapeutics: the middle of next year.

Brian Keveney, Chief Clinical Officer, Abeona Therapeutics: As Vish mentioned, we do have some discussions with the agency. We do not anticipate there’s no anticipation of any kind of inspection. It’s just additional conversations around the other parts of our facility being used for ZevaSkin manufacturing that we also use for our retrovirus manufacturing. So that’s really more of just a meeting with the agency. We don’t anticipate inspections necessary for that change.

And yes, we’re very bullish about our anticipated goal for the middle of next year meeting that 10 patient per month cadence.

Ram Selvaraju, Analyst, H.C. Wainwright: Great, really appreciate it guys. Congrats.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Thanks, Jeff.

Conference Operator: Thank you. Your next question is coming from James Molloy from Alliance Gold Partners. Your line is live.

James Molloy, Analyst, Alliance Gold Partners: Hey guys, thank you very much for taking my question. I was wondering, certainly been a great launch. I know it’s a different manufacturing process than the other competitor in the space. But how should we think about sort of their remarkable launch and expectations of how they should guide? Which we expect you guys over the next year or so, next two years for your initial stage of launch?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes, I think thanks for the question, Jim. We have been quite bold in how we articulated our launch in the sense that the patient demand is really what drives our strength here. And just within three months of approval to have the number of patients that might have communicated that are already identified as ZivaSkin, that’s what gives us the confidence that this is going to be growing as the first few patients go through this treatment experience. And, you know, we do feel that the unmet need still exists in the RDEF community. So we have so far communicated that our goal is to treat ten to 14 patients in V25, and, you know, the funnel is already building for more patients in 2026.

So in terms of a remarkable launch, I think for the early stages, I would say that we’ve removed all the hurdles for these patients to go through therapy, sites being ready, site activation is a progress right now. We already have two sites activated and we communicated that sufficient to hit the numbers for the shorter term, which is 2025. And then we will be announcing more sites activated. So by the end of the year, you’re going to actually see a lot more momentum having built at that point. And I could answer your question with more metrics for what a remarkable launch looks like.

The reason why we haven’t put any particular metric in place is because the compounding effect of so many variables not have explained what the treatment journey looks like. There’s a lot of time between various milestones in a patient’s journey to actually get to the treatment, and that’s getting shorter and shorter and shorter. So we will be able to give you more quantifiable ways of looking at what a remarkable launch would look like by the 2025. We don’t want to prematurely put numbers just because this is an unprecedented type of therapy and a patient population who has not experienced this at the scale that we are trying to achieve. So but the early trends are showing us good signs.

That’s all I would say about that because we’re not ready to give you any KPIs per se at this point in time. That is understandable. Thanks. Absolutely.

James Molloy, Analyst, Alliance Gold Partners: Thank you. I know you’re your hands full with the launch. Looking over the horizon or even over the pond, any thoughts on EU filing, EU partners, potential EU launch?

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: We are we have started some process of looking at EU as well as the Japan markets. The thing is, do we the big question is, do we supply from the Cleveland facility or do we have to build manufacturing footprint? The manufacturing footprint in a different geography is going to be a very long lead time, as you can imagine, because between the tech transfer and engineering runs and providing the data necessary for regulators to take action, you are looking at a three, four year time project. So we are actually looking at are there ways in which the Cleveland site can supply to other markets as well. And as you know, we are building capacity beyond the 10 a month and that project is already ongoing.

We are hoping that this is something that can be, at least not for all markets, but some select markets could be potentially supplied. And we’ll give you a little bit more of an update more towards the end of the year because we’re all so focused on The U. S. Launch first.

Conference Operator: Questions?

Joe Vazano, Chief Financial Officer, Abeona Therapeutics: Thank you.

Conference Operator: Thank you. Your next question is coming from Steven Wiley from Stifel. Your line is live.

Tully, Analyst, Stifel: Hey guys, thank you for taking my question again. Just one for Joe. How should we think about 2Q SG and A spend? Is that number a good surrogate for the next couple of quarters? Or should we expect that number to scale with an onboarding of additional Q2C things?

Joe Vazano, Chief Financial Officer, Abeona Therapeutics: Yes, that’s a good question. I mean, what I was alluding to on the call earlier is that as we’re doing the engineering run, those costs are SG and A. So the mix between R and D, COGS and SG and A will really vary depending on production output. So it’s kind of tough to forecast that. But as we’ve stated previously, three patients a month is our breakeven point.

So if you do the math on that, you can kind of see what our operating burn will be in a given year. It’s just that the mix between those three different expense items might fluctuate quarter by quarter.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Yes. It’s more of an accounting mix that shifts a little because of how the engineering runs were considered in the SG and A. But overall, operating cost is a good trend, what we’ve seen in the Q2 this year.

Conference Operator: Thank you. That concludes our Q and A session. I’ll now hand the conference back to Vish Deshadri for closing remarks. Please go ahead.

Vish Seshadri, Chief Executive Officer, Abeona Therapeutics: Thank you everyone for joining us in today’s business update. We’ll talk to you again soon.

Conference Operator: Thank you. Everyone, this concludes today’s event. You may disconnect at this time, and have a wonderful day. Thank you for your

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.